Café des Sciences Boston #51 – Recent progress in personalized medicine for lung cancer: “tailor-made” treatments for each patient

Published on Monday December 3, 2012
View online : https://www.france-science.org/Cafe-des-Sciences-Boston-51-Recent.html

The Boston Section of the Office for Science and Technology is co-organizing a Café des Sciences on December 12, 2012 with Dr. Stéphanie Cardarella of the Dana-Farber Cancer Institute and Brigham and Women’s Hospital on “Recent progress in personalized medicine for lung cancer treatment: “tailor-made” treatments for every patient.”

- **When:** Wednesday, December 12, 2012 – 6:00pm – 8:00pm
- **Where:** CIC Havana Room (5th Floor), One Broadway, Cambridge, MA 02142 (MAP)
- **Presentation in French**
- **RSVP**

**Presentation:**

For the past 30 years, lung cancer treatment has relied on conventional chemotherapy. Despite some progress in the development of the latest generation of molecules, treatment success seems to have reached a plateau. More recently, translational research has led to a better understanding of the molecular mechanisms that promote tumor cell growth. These advances have brought about the development of new, more rational treatments that attack the internal workings of lung cancer: targeted treatments. Dr. Cardarella will present the recent progress in personalized medicine for lung cancer: “tailor-made” treatments for each patient.

**Dr. Stéphanie Cardarella:**

With a medical degree from McGill University, Dr. Cardarella completed her residency in internal medicine at Beth Israel Deaconess Medical Center at Harvard University. She then continued with a fellowship in Medical Oncology at the Dana-Farber Cancer Institute, Brigham Women’s Hospital and Massachusetts General Hospital and performed clinical research with Dr. Bruce E. Johnson. In 2011, she joined the Dana-Farber Cancer Institute and Brigham and Women’s Hospital where she is a medical oncologist and clinical investigator in the Lowe Center for Thoracic Oncology. Dr. Cardarella’s research focuses on genomic changes in lung cancer, specific targeted treatments, and their impact on the likelihood of developing brain metastases.